# A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

> **NCT00118638** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 705 (actual)

## Conditions studied

- Anemia
- Non-Myeloid Malignancies

## Interventions

- **DRUG:** Darbepoetin alfa - 2.25 mcg/kg
- **DRUG:** Darbepoetin alfa - 500mcg

## Key facts

- **NCT ID:** NCT00118638
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2004-12
- **Final completion:** 2005-01
- **Target enrollment:** 705 (ACTUAL)
- **Last updated:** 2013-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118638, "A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00118638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*